Picture of Fabrinet logo

FN — Fabrinet News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyAdventurousLarge CapHigh Flyer

Fabrinet reports results for the quarter ended December 31 - Earnings Summary

* Fabrinet  FN.N  reported quarterly adjusted earnings of
$2.61​​
per share for the quarter ended December 31, higher than the
same quarter last year, when the company reported EPS of $2.08. 
The mean expectation of seven analysts for the quarter was
for earnings of $2.50 per share. Wall Street expected results to
range from $2.46  to $2.59 per share.
    * Revenue rose 17% to $833.61 million from a year ago;
analysts
expected $814.33 million. 
    * Fabrinet's reported EPS for the quarter was $2.38​.
    * The company reported quarterly net income of $86.64
million.
    * Fabrinet shares had fallen by 1.7% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.8%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the electronic
equipment & parts peer group is also "hold"

Wall Street's median 12-month price target for Fabrinet is
$280.00 
This summary was machine generated from LSEG data February 3 at
10:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      2.50           2.61           Beat
 Sep. 30 2024      2.38           2.39           Beat
 Jun. 30 2024      2.25           2.41           Beat
 Mar. 31 2024      2.11           2.39           Beat

Recent news on Fabrinet

See all news